People's Daily health client reporter Gao Ruirui
On April 13, the People's Daily Health Client learned from Luoxin Pharmaceutical Group that the 1 innovative drug Tegora tablets were approved for the treatment of reflux esophagitis, becoming China's first self-developed potassium ion competitive acid blocker (P-CAB). It has the characteristics of 30 minutes of rapid onset, strong and long-lasting acid suppression, and convenient administration.
The image comes from the website of Luoxin Pharmaceutical Group.
Reflux esophagitis is a common disease of the digestive system, which refers to the regurgitation of gastric contents into the esophagus, resulting in chronic inflammation caused by the breakdown of the mucosa of the esophagus, and in severe cases, it can be combined with esophageal ulcers, stenosis and even cancerous changes. Typical symptoms are heartburn, reflux, or other extraesophageal symptoms, with a prevalence of 6.4% in the general population of China1.
Clinical studies have shown that tegora tablets have a rapid onset of action in Chinese subjects, rapid onset of action in 30 minutes, and relief of symptoms such as heartburn reflux3, while other acid-suppressing drugs generally take 1.5 to 4 hours to take effect. At the same time, it is more convenient to take tigola raw and is not affected by eating time and metabolic genotype 4-5. In addition, many reflux patients at night heartburn reflux symptoms are particularly obvious, clinically this phenomenon is called nocturnal acid breakthrough, seriously affecting the quality of sleep, tigora tablets strong acid suppression, long-lasting effect, can more effectively control the phenomenon of nocturnal acid breakthrough.
According to reports, P-CAB tegora tablets belong to the national "major new drug creation" science and technology major special projects to support the research and development of high-tech achievements. After approval, the product is expected to be launched in some hospitals, pharmacies and Internet hospitals such as Jianke and Huiyi Tianxia in May, and will be supplied to patients for the first time.
bibliography:
1. Zou D, He J, Ma X, et al. Scand J Gastroenterol. 2011;46(2):133–41.
2.J Mermelstein, et al. Drugs Today (Barc). 2020 Nov;56(11):715-721.
3. He J, Cao G, Yu J, et al. Clin Drug Investig. 2021;41(1):89-97.
4.Sung arrow Han, et al. Clin Ther. 2021 Aug;43(8):1371-1380.
5.Eunsol Yang,et al. Br J Clin Pharmacol . 2022 Feb 10.
